Professional Documents
Culture Documents
LMA en Ancianos
LMA en Ancianos
DIANA OTERO D
Blood
Volume 113(18):4179-4187
April 30, 2009
Incidence of AML (non-APL) in 1997 to 2005 (new cases per 100 000 inhabitants, based on the
Swedish population in 2005) according to age and sex.
Early death rates (within 30 days from diagnosis) with intensive therapy according to age and
performance status.
Overall survival according to age irrespective of management (top, n = 2767), and patients
with de novo AML, fit for intensive treatment, and with WHO/ECOG performance status 0 to II
(bottom, n = 1229).
Overall survival according to WHO/ECOG performance status, only patients fit for intensive
treatment.
Overall survival of all patients, treated and untreated, 70 to 79 years of age according to
geographic region, with different proportions of patients given intensive therapy (Table 4).
Edad, Status
performance,
, cariotipo ,
LDH , Creat
> 1,3 ,
antecedente
de
enfermedad
hematologica
BAJAS DOSIS DE
CITARABINA
LDAC
20 mg /m2 1 -2 veces dia 10 -14 dias
8-18 %RC, prolongar supervivncia
Factores adversos menos remisin
Riesgo favorabl o intermedio +
condicin mdica
TERAPIA HIPOMETILANTE
DECITABINA
AZACITIDINA
7-24 %
Estudio AZA 001: Porlonga supervivencia 24
meses comparado con tratamiento convencional
Baja rata de RC
671 pacientes
AZA o decitabina
2000- 2010
Quimioterapia intensiva vs epigenetica
RC: 42 vs 28%
Mortalidad 8 sem: 19vs 20
No hubo diferencias en cuanto a lo citogenetico
Si WBC >
100 K Fallo
orgnico
Leucoaferesis
de
emergencia
Hidroxiurea
7+3
Cariotipo
favorable o
mutaciin
NPM1 sin
FLT3
Estudio
clinico con
7+3 IT o
7+3 solo
consolidacio
n
1. Geriatrico
2. caracterizacin Cariotipo y
molecular
Paciente
apto
Cariotipo
intermedi
o
Cariotip
o
Paciente
no apto /
frgil
FLT 3, ITD
mutacin
adverso
Cariotip
o
Cariotip
o
Estudio
clinico o
7+3 y
Dac/AZA
Estudio
clinico o
Dac/AZA
adverso
adverso
AlloSCT o
QT
Estudio clinico
o 7+3 y
Dac/AZA